Insider Buying: Profusa (NASDAQ:PFSA) Major Shareholder Acquires 14,556 Shares

Profusa, Inc. (NASDAQ:PFSA) major shareholder Financial Lp Hrt purchased 14,556 shares of Profusa stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $0.96 per share, for a total transaction of $13,973.76. Following the transaction, the insider directly owned 108,301 shares in the company, valued at approximately $103,968.96. The trade was a 15.53% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, August 4th, Financial Lp Hrt acquired 1,368 shares of Profusa stock. The shares were bought at an average price of $0.95 per share, with a total value of $1,299.60.
• On Wednesday, July 29th, Financial Lp Hrt acquired 1,310 shares of Profusa stock. The stock was bought at an average cost of $1.01 per share, for a total transaction of $1,323.10.

Profusa Price Performance

Shares of Profusa stock traded down $0.07 during midday trading on Wednesday, reaching $0.91. The company had a trading volume of 51,493 shares, compared to its average volume of 230,077. The stock has a fifty day moving average price of $3.90 and a 200 day moving average price of $34.82. Profusa, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $1,297.50. The firm has a market cap of $173,470.00, a PE ratio of -0.00 and a beta of 0.52.

Analyst Upgrades and Downgrades

PFSA has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Profusa in a research note on Wednesday, June 24th. Wall Street Zen raised shares of Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has an average rating of “Sell”.

Profusa Company Profile

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.